Levosulpiride for the treatment of diabetic macular oedema: a phase 2 randomized clinical trial.
Carlos D Núñez-AmaroMariana LópezElva Adán-CastroMa Ludivina Robles-OsorioRenata García-FrancoMarlon García-RoaYolanda Villalpando-GómezPaulina Ramírez-NeriaNayeli PineiroJuan Fernando Rubio MijangosJorge SánchezGabriela Ramírez-HernándezLourdes Siqueiros-MárquezNundehui Díaz-LezamaEllery López-StarThomas BertschGonzalo Marínez de la EscaleraJakob TriebelCarmen ClappPublished in: Eye (London, England) (2023)
Oral levosulpiride for 8 weeks improved visual and structural outcomes in patients with centre-involving DME by mechanisms that may include intraocular upregulation of vasoinhibin and downregulation of VEGF and PlGF. Larger clinical trials evaluating long-term efficacy and safety are warranted.
Keyphrases
- clinical trial
- cell proliferation
- signaling pathway
- cataract surgery
- type diabetes
- optical coherence tomography
- diabetic retinopathy
- vascular endothelial growth factor
- poor prognosis
- randomized controlled trial
- wound healing
- combination therapy
- metabolic syndrome
- phase ii
- study protocol
- replacement therapy
- glycemic control
- placebo controlled